'Consolidated net sales
(including other operating income) of Larsen & Toubro for the quarter ended
Dec 2023 has increased 18.84% to Rs 55127.82 crore. Operating profit
margin has declined by 50 bps to 10.4% and thus the growth at operating profit
restricted at 14% to Rs 5759 crore. Other
income rose 10.96% to Rs 837.75 crore. PBIDT rose 13% to Rs 6596.75
crore. Provision for interest fell 13% to Rs 904.17
crore. PBDT rose 13% to Rs 5692.58 crore. Provision for
depreciation rose 12% to Rs 920.75 crore. Profit before tax grew 14%
to Rs 4,771.83 crore. Provision for tax was expense of Rs 1177.32 crore,
compared to Rs 1270.5 crore. PAT was up 23% to Rs 3594.51 crore. Share of profit/loss was 77.64% higher at Rs
-1.67 crore. Minority interest increased 27.68% to Rs 645.48
crore. Net profit attributable to owners of the company increased 15%
to Rs...
Pleaselogin & subscribe to view the full report.
More Reports
-
(05-Nov-2024)
Gland Pharma
-
-
NII growth improves to 4% in Q2FY25
-
Revenue up 6.9% YoY to Rs 1064.0 cr, PAT up 4.5% YoY to Rs 307.9cr in Q2FY2025
|